QR-313, an antisense oligonucleotide, shows therapeutic efficacy for treatment of dominant and recessive dystrophic epidermolysis bullosa: a preclinical study

October 13th, 2020|Categories: Alternative splicing, Pre-Clinical Research, Splice modulation|

Bornert O, Hogervorst M, Nauroy P, Bischof J, Swildens J, Athanasiou I, Tufa SF, Keene DR, Kiritsi D, Hainzl S, Murauer EM, Marinkovich MP, Platenburg G, Hausser I, Wally V, Ritsema T, Koller U, Haisma EM, Nyström A. J Invest Dermatol. 2020 Sep 15:S0022-202X(20)32061-3. Pubmed [...]

Go to Top